Bone reports · 2026
The epidemiology of cancer patients with proximal femoral lesions and evaluation of surgical decision tools: A prospective cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sternheim Amir, Yosibash Zohar, Milgrom Charles, Trabelsi Nir, Ariel Gal, Merose Omri, Gortzak Yair, Finestone Aharon S
Аннотация
INTRODUCTION: This study evaluated the outcomes of orthopaedic oncological surgical decisions in cancer patients with proximal femoral lesions and the accuracy of fracture prediction tools.
METHODS: Patients with proximal femur metastatic cancer or multiple myeloma lesions presenting for prophylactic surgical evaluation between March 2018 and July 2023 were recruited with follow-up until March 2026. Femoral fracture risk was evaluated using CT finite element analysis (CTFEA) and Mirels' score. Patients were randomized, enabling 2/3 of their surgeons to receive the results of their CTFEA.
RESULTS: One hundred and ten patients completed the study. The patient 36-month patient survival rate from the time of orthopaedic oncology referral was 44%, with no difference in the survival estimates of patients who underwent prophylactic surgery and patients with no surgery (P = 0.8. Four patients fractured. CTFEA predicted fracture in all and Mirels' score in two. There was no statistically significant difference between the sensitivity (100% vs 50%), specificity (72% vs 70%), positive prediction value (27% vs 13%), and negative prediction value (100% vs 94%) between CTFEA and the Mirels' score. CTFEA advised surgery in 57% (36/63) patients, but in only 27/36, was the clinical decision surgery.
CONCLUSION: Compared to publications prior to modern therapy, patient survival improved. Having prophylactic proximal femur surgery because of metastasis was not found to affect survival time. While CTFEA correctly identified all four fracture patients, following its prophylactic surgery recommendations would have led to unnecessary surgeries. Orthopaedic oncologists disregarded the CTFEA recommendation to perform surgery in 25% of patients.
METHODS: Patients with proximal femur metastatic cancer or multiple myeloma lesions presenting for prophylactic surgical evaluation between March 2018 and July 2023 were recruited with follow-up until March 2026. Femoral fracture risk was evaluated using CT finite element analysis (CTFEA) and Mirels' score. Patients were randomized, enabling 2/3 of their surgeons to receive the results of their CTFEA.
RESULTS: One hundred and ten patients completed the study. The patient 36-month patient survival rate from the time of orthopaedic oncology referral was 44%, with no difference in the survival estimates of patients who underwent prophylactic surgery and patients with no surgery (P = 0.8. Four patients fractured. CTFEA predicted fracture in all and Mirels' score in two. There was no statistically significant difference between the sensitivity (100% vs 50%), specificity (72% vs 70%), positive prediction value (27% vs 13%), and negative prediction value (100% vs 94%) between CTFEA and the Mirels' score. CTFEA advised surgery in 57% (36/63) patients, but in only 27/36, was the clinical decision surgery.
CONCLUSION: Compared to publications prior to modern therapy, patient survival improved. Having prophylactic proximal femur surgery because of metastasis was not found to affect survival time. While CTFEA correctly identified all four fracture patients, following its prophylactic surgery recommendations would have led to unnecessary surgeries. Orthopaedic oncologists disregarded the CTFEA recommendation to perform surgery in 25% of patients.